April 2, 2020 10:28 AM EDT

Sue Desmond-Hellmann joins Pfizer board; Kite Pharma taps ally in push to expand CAR-T

ENDPOINTS

→ Sue Desmond-Hellmann will be joining Pfizer’s board of directors, four months after stepping down as CEO of the Bill and Melinda Gates Foundation …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sue Desmond-Hellmann joins Pfizer board; Kite Pharma taps ally in push to expand CAR-T

ENDPOINTS

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Sue Desmond-Hell­mann joins Pfiz­er board; Kite Phar­ma taps al­ly in push to ex­pand CAR-T

ENDPOINTS

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Sue Desmond-Hellmann joins Pfizer board; Kite Pharma taps ally in push to expand CAR-T

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?